Is continuous infusion of β-lactam antibiotics worthwhile ? : efficacy and pharmacokinetic considerationsMOUTON, J. W; VINKS, A. A. T. M. M.Journal of antimicrobial chemotherapy (Print). 1996, Vol 38, Num 1, pp 5-15, issn 0305-7453Article

Can tobramycin inhalation be improved with a jet nebulizer?LE BRUN, P. P. H; VINKS, A. A. T. M. M; TOUW, D. J et al.Therapeutic drug monitoring. 1999, Vol 21, Num 6, pp 618-624, issn 0163-4356Article

Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis: Current practice and suggestions for future directionsTOUW, D. J; VINKS, A. A. T. M. M; MOUTON, J. W et al.Clinical pharmacokinetics. 1998, Vol 35, Num 6, pp 437-459, issn 0312-5963Article

Prospective evaluation of a dose prediction algorithm for intravenous tobramycin in adolescent and adult patients with cystic fibrosisTOUW, D. J; VINKS, A. A. T. M. M; HEIJERMAN, H. G. M et al.Therapeutic drug monitoring. 1996, Vol 18, Num 2, pp 118-123, issn 0163-4356Article

Comparison of two intravenous ranitidine regimens in a homogeneous population of intensive care unit patientsGEUS, W. P; VINKS, A. A. T. M. M; SMITH, S. J et al.Alimentary pharmacology & therapeutics. 1993, Vol 7, Num 4, pp 451-457, issn 0269-2813Article

Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosisTOUW, D. J; VINKS, A. A. T. M. M; HEIJEMAN, H. G. M et al.Therapeutic drug monitoring. 1993, Vol 15, Num 1, pp 52-59, issn 0163-4356Article

Pharmacokinetics of tobramycin in adults with cystic fibrosis : Implications for once-daily administrationBERINGER, P. M; VINKS, A. A. T. M. M; JELLIFFE, R. W et al.Antimicrobial agents and chemotherapy. 2000, Vol 44, Num 4, pp 809-813, issn 0066-4804Article

Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategyVINKS, A. A. T. M. M; MOUTON, J. W; TOUW, D. J et al.Antimicrobial agents and chemotherapy. 1996, Vol 40, Num 5, pp 1091-1097, issn 0066-4804Article

Some international approaches to aminoglycoside monitoring in the extended dosing interval eraMORRIS, R. G; SALLUSTIO, B. C; VINKS, A. A. T. M. M et al.Therapeutic drug monitoring. 1999, Vol 21, Num 4, pp 379-388, issn 0163-4356Conference Paper

Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment : clinical outcome, microbiology and pharmacokineticsVINKS, A. A. T. M. M; BRIMICOMBE, R. W; HEIJERMAN, H. G. M et al.Journal of antimicrobial chemotherapy (Print). 1997, Vol 40, Num 1, pp 125-133, issn 0305-7453Article

Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosisTOUW, D. J; VINKS, A. A. T. M. M; JACOBS, F et al.Therapeutic drug monitoring. 1996, Vol 18, Num 5, pp 562-569, issn 0163-4356Article

Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at homeVINKS, A. A. T. M. M; TOUW, D. J; HEIJERMAN, H. G. M et al.Therapeutic drug monitoring. 1994, Vol 16, Num 4, pp 341-348, issn 0163-4356Article

Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosisTOUW, D. J; VINKS, A. A. T. M. M; HEIJERMAN, H. G. M et al.Therapeutic drug monitoring. 1994, Vol 16, Num 2, pp 125-131, issn 0163-4356Article